ij³ª´Ù ÃÖ´ë ±Ô¸ðÀÇ »óó Ä¡·á ÄÁÆÛ·±½º¿¡¼ 5ȸÀÇ ÀÓ»ó °¿¬ ¹× Æ÷½ºÅ͵éÀ» ÅëÇØ ¸¸¼º »óó¸¦ À§ÇÑ POC(ÇöÀåÁø´Ü) Çü±¤ À̹Ì¡ ¹× ±× Áß¿äÇÑ ÀÓ»óÀû ÀÌÁ¡µéÀÌ ¼Ò°³µÇ¾ú´Ù. ¸¸¼º »óóµé¿¡¼ ¹ß°ßµÇ´Â ¹ÚÅ׸®¾ÆµéÀ» ½Ç½Ã°£À¸·Î ½Ã°¢ÈÇÏ´Â ÈÞ´ë¿ë Çü±¤ À̹Ì¡ ºÐ¾ß¸¦ À̲ø¾î °¡´Â ±Û·Î¹ú À¯¼öÀÇ ±â¾÷ÀÎ ¸ô·¹Å¥¶óÀÌÆ®(MolecuLight Inc.)¿Í ´ç»çÀÇ ¾ÆÀÌ¿¢½º POC(ÇöÀåÁø´Ü) Çü±¤ À̹Ì¡ ÀåÄ¡°¡ 2019 ¿îÁî ij³ª´Ù ¿¬·Ê ÄÁÆÛ·±½º(Wounds Canada 2019 Annual Conference)¿¡ Âü°¡ÇÑ´Ù. ÇØ´ç ÄÁÆÛ·±½º´Â ij³ª´Ù ÃÖ´ëÀÇ »óó Ä¡·á ÀÓ»ó ÄÁÆÛ·±½º·Î 2019³â 10¿ù 4ÀÏ¿¡¼ 6ÀϱîÁö ¿ÂŸ¸®¿ÀÁÖÀÇ ³ªÀ̾ư¡¶ó ÆøÆ÷¿¡¼ °³ÃֵȴÙ.
|
|
|
¡ã ¸ô·¹Å¥¶óÀÌÆ® ¾ÆÀÌ¿¢½º(MolecuLight i:X®) Çü±¤ À̹Ì¡ ½Ã½ºÅÛ |
"2019 ¿îÁî ij³ª´Ù(Wound Canada 2019)¿¡¼ Àü ¼¼°è ¼ö ¸¹Àº °í°´µéÀÌ °øÀ¯ÇÑ ¸ô·¹Å¥¶óÀÌÆ® ¾ÆÀÌ¿¢½º(MolecuLight i:X) Çü±¤ À̹Ì¡ Ç÷§ÆûÀÌ Á¦°øÇÏ´Â ÀÇ¹Ì ÀÖ´Â ÀÓ»óÀû ÇýÅõ鿡 ´ëÇØ ¹ßÇ¥ÇÏ°Ô µÇ¾î ¸Å¿ì ±â»Ú´Ù" ¸é¼ "´Ù¼öÀÇ ÀÓ»ó ¿¬±¸µé·ÎºÎÅÍ ¾òÀº ¼º°øÀûÀÎ °á°úµéÀº, ¼·Î ´Ù¸¥ ´Ù¼öÀÇ ¿î¿µÀÚµé ±×¸®°í ´Ù¾çÇÑ ÀÓ»ó ȯ°æ¿¡¼ Çü±¤ À̹Ì¡ÀÌ ¾î¶»°Ô ¸¸¼º »óó °ü¸®¿¡ ½Ç½Ã°£À¸·Î ½ÇÁúÀûÀÎ ÀÌÁ¡µéÀ» Á¦°øÇÒ ¼ö ÀÖ´ÂÁö¸¦ º¸¿©ÁØ´Ù"°í ¸ô·¹Å¥¶óÀÌÆ®ÀÇ CEOÀÎ ¾Ö´Ò ¾Ï·¡´Ï(Anil Amlani)´Â ÀüÇß´Ù.
¸ô·¹Å¥¶óÀÌÆ® ¾ÆÀÌ¿¢½º(MolecuLight i:X) Çü±¤ À̹Ì¡ ±â±âµé¿¡ ´ëÇÑ 5°³ÀÇ ÀÓ»ó ÇÁ·¹Á¨Å×À̼ǵéÀº ¾Æ·¡¿Í °°´Ù.
• "¹ÚÅ׸®¾Æ Çü±¤ Á¤º¸¸¦ »ó/ÇÏ(UPPER/LOWER) °¨¿° üũ¸®½ºÆ®¿¡ ÅëÇÕÇÑ ÀüÇâÀû ´ÙÁß »çÀÌÆ® °üÂû ¿¬±¸(A prospective multi-site observational study incorporating bacterial fluorescence information into the UPPER/LOWER infection checklists)", ·ÎÁ¸® Èú°ú Äɺó ¿ì(Rosemary Hil, Kevin Woo)
• "½ºÆ©¾îµå½Ê°ú Çâ¹Ì»ý¹° ÀÇ»ç°áÁ¤ÀÇ ¹ÚÅ׸®¾Æ Çü±¤ À̹ÌÁö °¡ÀÌ´ø½º: 350¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ´Â ´ÙÁß È¯°æ ÀÓ»ó½ÃÇè (Bacterial fluorescence image guidance of antimicrobial decision-making and stewardship: A 350-patient multi-site clinical trial)", Å丶½º ¼¼·¹³ª ¿Ü(Thomas Serena et al.)
• "½Ç½Ã°£ ¹ÚÅ׸®¾Æ Çü±¤ À̹Ì¡À¸·Î Æ÷¸£ÇǸ°-»ý¼º »óó º´¿øü, ÇöûÅ©Åæ, »ý¹°¸·ÀÇ »ýü ³» ±×¸®°í ½ÃÇè°ü ³» °ËÃâ(In vivo and in vitro detection of porphyrin-producing wound pathogens, planktonic and in biofilm, with real-time bacterial fluorescence imaging)", ·Î¶ó Á¸½¼, ¾Ù¸® ½º¹Ì½º ¿Ü(Laura M. Jones, Allie C. Smith et al.)
• "¸¸¼º »óó¿¡ ´ëÇÑ Á¤·ÊÀûÀÎ Æò°¡·Î, ÇöÀå Ä¡·á À̹Ì¡ ±â±â¿Í »óóÀÇ Å©±â¿Í ¹ÚÅ׸®¾Æ Çü±¤ Á¤º¸¸¦ È¿À²ÀûÀ¸·Î ÅëÇÕ °¡´É(Routine assessment of chronic wounds can efficiently incorporate wound size and bacterial fluorescence information with a point-of-care imaging device)", ·Î¶ó Á¸½¼, ·Ð ¸°µ§ ¿Ü(Laura M. Jones, Ron Linden et al.)
• "»óó Æò°¡ Æз¯´ÙÀÓ Àüȯ: ¹ÚÅ׸®¾Æ Çü±¤ À̹Ì¡À» Ç¥ÁØ Ä¡·á¿¡ ÅëÇÕÇÏ´Â 350¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ´Â ´ÙÁß È¯°æ ÀÓ»ó½ÃÇè(Wound assessment paradigm shift: a 350-patient multi-site clinical trial incorporating bacterial fluorescence imaging into standard of care)", Å丶½º ¼¼·¹³ª ¿Ü(Thomas Serena et al.)
ÇÁ·¹Á¨Å×ÀÌ¼Ç ¿Ü¿¡µµ (¿ÂŸ¸®¿ÀÁÖ ³ªÀ̾ư¡¶óÆøÆ÷, Æú½ººä Ä«Áö³ë ¸®Á¶Æ®ÀÇ ±×·£µåȦ CDE) Àü½Ã°ü¿¡¼ ¸ô·¹Å¥¶óÀÌÆ®ÀÇ 905¹ø ºÎ½º(Booth # 905)¸¦ ¹æ¹®Çϸé ÇØ´ç ¾ÆÀÌ¿¢½º(i:X) ±â±â¸¦ üÇè »ç¿ë Çغ¼ ¼ö ÀÖ´Ù.
¸ô·¹Å¥¶óÀÌÆ®(MolecuLight Inc.)
ij³ª´ÙÀÇ ºñ»óÀå ÀÇ·á À̹Ì¡ ±â¾÷ÀÎ ¸ô·¹Å¥¶óÀÌÆ®(MolecuLight Inc.)´Â ´Ù¼öÀÇ ÀÓ»ó ¹× »ó¾÷ ½ÃÀåµé¿¡¼ µ¶Á¡ Çü±¤ À̹Ì¡ Ç÷§Æû ±â¼úÀ» °³¹ßÇÏ°í »ó¿ëÈÇÑ´Ù. ¸ô·¹Å¥¶óÀÌÆ®ÀÇ Ãʱâ Á¦Ç° ¹× ¾×¼¼¼¸®ÀÎ ¸ô·¹Å¥¶óÀÌÆ® ¾ÆÀÌ¿¢½º(MolecuLight i:X®)´Â Àü ¼¼°è¿¡ ½Ç½Ã°£ ÈÞ´ë¿ë Çü±¤ À̹Ì¡ ¼Ö·ç¼ÇÀ» Á¦°øÇØ »óóÀÇ Áø´Ü ¹× Ä¡·á¸¦ Áö¿øÇÑ´Ù. ÀÓ»óÀǵ鿡°Ô ȸéÀ» ÅëÇØ »óóºÎÀ§¿¡ ³ªÅ¸³ª´Â Çü±¤ Ư¼º¿¡ ´ëÇÑ »õ·Î¿î Á¤º¸¸¦ Á¦°øÇØ ÀÓ»óÀǵéÀÌ ÃÖ¼±ÀÇ Áø´Ü ¹× Ä¡·á °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½´Â´Ù. ¶ÇÇÑ ½ÄÇ°¾ÈÀü, ¼ÒºñÀÚ ÈÀåÇ° ¹× ±âŸ ÁÖ¿ä »ê¾÷ ½ÃÀåµéÀ» Æ÷ÇÔÇØ ÃæÁ·µÇÁö ¾ÊÀº ¿ä±¸»çÇ×µéÀÌ ÀÖ´Â Àü ¼¼°è ±âŸ ½ÃÀåµéÀ» À§ÇØ °íÀ¯ÀÇ Çü±¤ À̹Ì¡ Ç÷§Æû ±â¼úÀ» »ó¿ëÈÇÑ´Ù.
[Çì¸ð¶óÀÌÇÁ Çϼ®Âù ±âÀÚ]
< ÀúÀÛ±ÇÀÚ © Çì¸ðÇʸ®¾Æ ¶óÀÌÇÁ ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |